Patents by Inventor John G. Flannery

John G. Flannery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 11565001
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: January 31, 2023
    Assignees: The Regents of the University of California, The Trustees of the University of Pennsylvania
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 11565000
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: January 31, 2023
    Assignees: The Regents of the University of California, The Trustees of the University of Pennsylvania
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 11554180
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: January 17, 2023
    Assignees: The Regents of the University of California, The Trustees of the University of Pennsylvania
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF
    Publication number: 20220362409
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: June 16, 2022
    Publication date: November 17, 2022
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF
    Publication number: 20220331451
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 20, 2022
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF
    Publication number: 20220331450
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 20, 2022
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • Adeno-Associated Virus Virions with Variant Capsid and Methods of Use Thereof
    Publication number: 20220243291
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: December 14, 2021
    Publication date: August 4, 2022
    Inventors: David V. SCHAFFER, Ryan R. KLIMCZAK, James T. KOERBER, John G. FLANNERY, Deniz DALKARA MOUROT, Meike Visel, Leah C.T. BYRNE
  • Adeno-associated virus virions with variant capsid
    Patent number: 11236402
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSIDS AND METHODS OF USE THEREOF
    Publication number: 20210371879
    Abstract: The present disclosure provides recombinant adeno-associated virus (AAV) virions comprising: a) a variant capsid protein; and b) a heterologous nucleic acid comprising one or more nucleotide sequences encoding one or more heterologous gene products. The rAAV virions are useful for delivery of gene products to a retinal cell. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
    Type: Application
    Filed: May 27, 2021
    Publication date: December 2, 2021
    Inventors: John G. Flannery, Scott F. Geller, Karen I. Guerin
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF
    Publication number: 20210283274
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: July 27, 2017
    Publication date: September 16, 2021
    Inventors: David V. Schaffer, John G. Flannery, William A. Beltran, Leah C. Byrne, Meike Visel
  • COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION
    Publication number: 20200339641
    Abstract: The present disclosure provides a method of restoring or enhancing visual function in an individual, the method comprising administering to the individual a nucleic acid comprising a nucleotide sequence encoding one or more of a medium wavelength cone opsin (MW-opsin), a long wavelength cone opsin (LW-opsin), and a short wavelength cone opsin (SW-opsin). One or more of the MW-opsin, LW-opsin, and SW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 29, 2020
    Inventors: Ehud Y. Isacoff, Michael H. Berry, Amy Holt, Meike Visel, Autoosa Salari, John G. Flannery, Benjamin M. Gaub
  • Compositions and methods for enhancing visual function
    Patent number: 10745453
    Abstract: The present disclosure provides a method of restoring or enhancing visual function in an individual, the method comprising administering to the individual a nucleic acid comprising a nucleotide sequence encoding one or more of a medium wavelength cone opsin (MW-opsin), a long wavelength cone opsin (LW-opsin), and a short wavelength cone opsin (SW-opsin). One or more of the MW-opsin, LW-opsin, and SW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: August 18, 2020
    Assignee: The Regents of the University of California
    Inventors: Ehud Y. Isacoff, Michael H. Berry, Amy Holt, Meike Visel, Autoosa Salari, John G. Flannery, Benjamin M. Gaub
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF
    Publication number: 20200231942
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: October 24, 2019
    Publication date: July 23, 2020
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSIDS AND METHODS OF USE THEREOF
    Publication number: 20200121746
    Abstract: The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.
    Type: Application
    Filed: June 28, 2018
    Publication date: April 23, 2020
    Inventors: David V. Schaffer, Leah C. Byrne, Timothy P. Day, John G. Flannery
  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 10494612
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery
  • ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF
    Publication number: 20190218627
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 18, 2019
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C.T. Byrne
  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 10214785
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 26, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 10202657
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: February 12, 2019
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 9856539
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: January 2, 2018
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Adeno-associated virus virions with variant capsid and methods of use thereof
    Patent number: 9587282
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 7, 2017
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne